{"id":82760,"date":"2019-05-27T00:00:00","date_gmt":"2022-11-09T14:20:23","guid":{"rendered":"https:\/\/mdbc1.wpengine.com\/?post_type=eb_course&p=82760"},"modified":"2023-05-02T09:28:19","modified_gmt":"2023-05-02T13:28:19","slug":"insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro","status":"publish","type":"eb_course","link":"https:\/\/www.mdbriefcase.com\/fr\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/","title":{"rendered":"Insuline et diab\u00e8te de type 2 \u2013 Prise en charge transform\u00e9e par les nouvelles options th\u00e9rapeutiques – Mainpro+"},"content":{"rendered":"

Lorsqu\u2019une personne re\u00e7oit un diagnostic de diab\u00e8te de type 2, on pr\u00e9sume qu\u2019elle a perdu entre 50% et 80% de la capacit\u00e9 fonctionnelle des cellules b\u00eata. Cette capacit\u00e9 fonctionnelle continuera de se d\u00e9t\u00e9riorer durant le cours de la maladie. Lorsque la production maximale d\u2019insuline aura diminu\u00e9 \u00e0 15 % ou \u00e0 20 % de la production normale, les agents antihyperglyc\u00e9miants non-insuliniques ne pourront plus assurer la ma\u00eetrise de la glyc\u00e9mie; la suppl\u00e9mentation en insuline deviendra alors une n\u00e9cessit\u00e9.<\/p>","protected":false},"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","eb_course_cat":[],"class_list":["post-82760","eb_course","type-eb_course","status-publish","hentry"],"acf":[],"yoast_head":"\nInsuline et diab\u00e8te de type 2 \u2013 Prise en charge transform\u00e9e par les nouvelles options th\u00e9rapeutiques - Mainpro+ - MDBriefCase<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insuline et diab\u00e8te de type 2 \u2013 Prise en charge transform\u00e9e par les nouvelles options th\u00e9rapeutiques - Mainpro+ - MDBriefCase\" \/>\n<meta property=\"og:description\" content=\"Lorsqu\u2019une personne re\u00e7oit un diagnostic de diab\u00e8te de type 2, on pr\u00e9sume qu\u2019elle a perdu entre 50% et 80% de la capacit\u00e9 fonctionnelle des cellules b\u00eata. Cette capacit\u00e9 fonctionnelle continuera de se d\u00e9t\u00e9riorer durant le cours de la maladie. Lorsque la production maximale d\u2019insuline aura diminu\u00e9 \u00e0 15 % ou \u00e0 20 % de la […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/\" \/>\n<meta property=\"og:site_name\" content=\"MDBriefCase\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-02T13:28:19+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/\",\"url\":\"https:\/\/www.mdbriefcase.com\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/\",\"name\":\"Insuline et diab\u00e8te de type 2 \u2013 Prise en charge transform\u00e9e par les nouvelles options th\u00e9rapeutiques - Mainpro+ - MDBriefCase\",\"isPartOf\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#website\"},\"datePublished\":\"2022-11-09T14:20:23+00:00\",\"dateModified\":\"2023-05-02T13:28:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mdbriefcase.com\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mdbriefcase.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Course\",\"item\":\"https:\/\/www.mdbriefcase.com\/courses\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Insuline et diab\u00e8te de type 2 \u2013 Prise en charge transform\u00e9e par les nouvelles options th\u00e9rapeutiques – Mainpro+\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#website\",\"url\":\"https:\/\/www.mdbriefcase.com\/\",\"name\":\"MDBriefCase\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mdbriefcase.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#organization\",\"name\":\"MDBriefCase\",\"url\":\"https:\/\/www.mdbriefcase.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"contentUrl\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"width\":190,\"height\":36,\"caption\":\"MDBriefCase\"},\"image\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Insuline et diab\u00e8te de type 2 \u2013 Prise en charge transform\u00e9e par les nouvelles options th\u00e9rapeutiques - Mainpro+ - MDBriefCase","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mdbriefcase.com\/fr\/cours\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/","og_locale":"fr_CA","og_type":"article","og_title":"Insuline et diab\u00e8te de type 2 \u2013 Prise en charge transform\u00e9e par les nouvelles options th\u00e9rapeutiques - Mainpro+ - MDBriefCase","og_description":"Lorsqu\u2019une personne re\u00e7oit un diagnostic de diab\u00e8te de type 2, on pr\u00e9sume qu\u2019elle a perdu entre 50% et 80% de la capacit\u00e9 fonctionnelle des cellules b\u00eata. Cette capacit\u00e9 fonctionnelle continuera de se d\u00e9t\u00e9riorer durant le cours de la maladie. Lorsque la production maximale d\u2019insuline aura diminu\u00e9 \u00e0 15 % ou \u00e0 20 % de la […]","og_url":"https:\/\/www.mdbriefcase.com\/fr\/cours\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/","og_site_name":"MDBriefCase","article_modified_time":"2023-05-02T13:28:19+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mdbriefcase.com\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/","url":"https:\/\/www.mdbriefcase.com\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/","name":"Insuline et diab\u00e8te de type 2 \u2013 Prise en charge transform\u00e9e par les nouvelles options th\u00e9rapeutiques - Mainpro+ - MDBriefCase","isPartOf":{"@id":"https:\/\/www.mdbriefcase.com\/#website"},"datePublished":"2022-11-09T14:20:23+00:00","dateModified":"2023-05-02T13:28:19+00:00","breadcrumb":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mdbriefcase.com\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.mdbriefcase.com\/courses\/insuline-et-diabete-de-type-2-prise-en-charge-transformee-par-les-nouvelles-options-therapeutiques-mainpro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mdbriefcase.com\/"},{"@type":"ListItem","position":2,"name":"Course","item":"https:\/\/www.mdbriefcase.com\/courses\/"},{"@type":"ListItem","position":3,"name":"Insuline et diab\u00e8te de type 2 \u2013 Prise en charge transform\u00e9e par les nouvelles options th\u00e9rapeutiques – Mainpro+"}]},{"@type":"WebSite","@id":"https:\/\/www.mdbriefcase.com\/#website","url":"https:\/\/www.mdbriefcase.com\/","name":"MDBriefCase","description":"","publisher":{"@id":"https:\/\/www.mdbriefcase.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mdbriefcase.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.mdbriefcase.com\/#organization","name":"MDBriefCase","url":"https:\/\/www.mdbriefcase.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","width":190,"height":36,"caption":"MDBriefCase"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/82760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course"}],"about":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/types\/eb_course"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/comments?post=82760"}],"version-history":[{"count":0,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/82760\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media?parent=82760"}],"wp:term":[{"taxonomy":"eb_course_cat","embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course_cat?post=82760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}